ACM
KALV

Altium Capital Management’s KalVista Pharmaceuticals KALV Stock Holding History

Altium Capital Management’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-111,834
Closed -$1.48M – 140
2021
Q4 		$1.48M Hold
111,834
– – 0.41% 79
2021
Q3 		$1.95M Hold
111,834
– – 0.51% 77
2021
Q2 		$2.68M Sell
111,834
-16,296
-13% -$426K 0.62% 66
2021
Q1 		$3.29M Buy
+128,130
New +$3.37M 0.91% 44

Other funds holding KALV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Altium Capital Management's KALV Position: Q1 2022 in Review

Altium Capital Management sold out of KalVista Pharmaceuticals (KALV) in Q1 2022, closing a stake of 111,834 shares — an estimated $1.48M sold.

Altium Capital Management first reported a position in KALV in Q1 2021 and held it in 4 quarters. The position peaked at $3.29M in Q1 2021. 89 funds tracked by Wall St. Rank hold KALV as of Q1 2022.

  • Altium Capital Management reported no remaining KalVista Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Altium Capital Management sold 111,834 KalVista Pharmaceuticals shares in Q1 2022, an estimated $1.48M.
  • Altium Capital Management first reported a position in KalVista Pharmaceuticals in Q1 2021 and held it in 4 quarters.
  • Altium Capital Management's KalVista Pharmaceuticals position peaked at $3.29M in Q1 2021.
  • 89 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2022.

Based on Altium Capital Management's 13F filing for Q1 2022, filed 16 May 2022.